Literature DB >> 19759045

Off-label use of antibiotics in hospitalized patients: focus on tigecycline.

Daniel Curcio1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759045     DOI: 10.1093/jac/dkp342

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

1.  The ribosomal S10 protein is a general target for decreased tigecycline susceptibility.

Authors:  Kathryn Beabout; Troy G Hammerstrom; Anisha Maria Perez; Bárbara Freitas Magalhães; Amy G Prater; Thomas P Clements; Cesar A Arias; Gerda Saxer; Yousif Shamoo
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

Review 2.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Burcu Isler; Yohei Doi; Robert A Bonomo; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

3.  Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections: cefoperazone-sulbactam associated with resistance and tigecycline increased the mortality.

Authors:  Tianshui Niu; TingTing Xiao; Lihua Guo; Wei Yu; Yunbo Chen; Beiwen Zheng; Chen Huang; Xiao Yu; Yonghong Xiao
Journal:  Infect Drug Resist       Date:  2018-10-26       Impact factor: 4.003

4.  Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant Klebsiella Pneumoniae: Exploring A Colistin Sparing Protocol.

Authors:  Manawr Al-Quraini; Meher Rizvi; Zaaima Al-Jabri; Hiba Sami; Muna Al-Muzahmi; Zakariya Al-Muharrmi; Neelam Taneja; Ibrahim Al-Busaidi; Rajeev Soman
Journal:  Antibiotics (Basel)       Date:  2022-01-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.